Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow...
Transcript of Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow...
![Page 1: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/1.jpg)
Characterization of
Biologics Using
Agilent TOF
Systems
Dawn Stickle, Ph.D.
December 2013
Center of Excellence
Agilent Technologies
Wilmington, DE
![Page 2: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/2.jpg)
Agilent’s Tools and Technologies for
BioPharmaceutical Analyses
Agilent’s broad technology portfolio includes:
• Liquid chromatography
• LC/MS
• Capillary electrophoresis
• Ion analysis (CE and HPLC)
• Isoelectric focusing
• Evaporative light scattering
• Gas chromatography
• GC/MS
• qPCR
• LC column technology (reversed phase, ion exchange and size exclusion)
• Protein standards and protein processing kits
• Lab-on-a-Chip
![Page 3: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/3.jpg)
Agilent LC/MSD TOF
Two Stage Ion
Mirror
5 Stage Vacuum System
Agilent Orthogonal
Spray Source(s)
Optically Coupled
Ion Detector
Beam cooling
and guidance
Effective Flight Path
Length of 2.0m Low-expansion
Flight Tube
Design Optimizes Ion Transmission and
Mass Resolving Power
![Page 4: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/4.jpg)
BioPharma – Description and Workflow Description
• Characterization of Proteins at the intact or digest level, or synthetic peptides.
• Provide target sequence(s), and analyze intact protein mixture, or after digestion.
• Find all peptides (MFE) or proteins (LMFE) and match to target sequence while applying
rules for modifications (truncations, PTMs).
Workflow
• Acquire sample with intact protein, protein digest, synthetic peptide or oligo in MS
• Enter sequence of peptide, protein or oligo in MassHunter BioConfirm and set up rules.
• Analyze sample, which matches the found masses to the supplied sequence.
• Optionally acquire MS/MS spectra of compounds in question and use Spectrum Mill
• Print report
Easy Access
Smpl + Seq Setup rules
+sequences
Acq MSMS for
Spectrum Mill Worklist
Sample + Seq
Report Match
sequence
Turnkey Automation
![Page 5: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/5.jpg)
Intact mAb Analysis
![Page 6: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/6.jpg)
Structure and Modifications of Antibody
• Analyze intact antibody
•Analyze deglycosylated
antibody (enzymatic)
•Analyze reduced antibody
(light and heavy chains)
•Analyze Fab and Fc
regions (papain cleavage)
Light Chain
Fc
Fab
Antigen
binding
Hinge
Glycosylation
site Truncation
(lysine)
Disulfide
shuffling
Pyroglutamate
Deamidation/oxidation
Heavy Chain
Fucose – 146Da
Mannose – 162da
N-Acetylglucosamine – 203Da
Galactose – 162Da
![Page 7: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/7.jpg)
1. Mass Spectrum of a mAb – 10 ng on Zorbax SB300-C18
HPLC-Chip
![Page 8: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/8.jpg)
Deconvoluted Mass Spectrum of Intact mAb – 10ng on
Zorbax SB300-C18 HPLC Chip
Mcalc: 148811.95
Mexp: 148812.81
Error: 5.8ppm
Δ1444.87
Δ2890.81
G0F/G0F x104
0
1
2
3
4
5
6
6.5
148812.81
145922.00
147367.94
146329.69
146816.21
147719.65
Counts vs. Deconvoluted Mass (amu)
145500 146000 146500 147000 147500 148000 148500 149000 149500 150000 150500 151000 151500
5.5
4.5
3.5
2.5
1.5
0.5
Δ 162.2 hexose unit
x104
0
1
2
3
4
5
6
7
8
148812.81
148974.97 148840.65 148916.37
148765.43
Counts vs. Deconvoluted Mass (amu)
148750 148800 148850 148900 148950
G0F/G0F
G0F/G1F
![Page 9: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/9.jpg)
Deconvoluted Mass Spectrum of Deglycosylated mAb –
PNGaseF treated
No glycan-attached species
4 x10
0
1
2
3
4
5
6
7
8
145924.41
146272.08
Counts vs. Deconvoluted Mass (amu)
144500 145000 145500 146000 146500 147000 147500 148000 148500 149000 149500
Mcalc: 145923.24
Mexp: 145924.41
Error: 8ppm
![Page 10: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/10.jpg)
DTT Reduced mAb: Deconvoluted Spectrum of Light Chain
5 x10
0
1
2
3
4
5
23746.50
23727.82 23762.96
Counts vs. Deconvoluted Mass (amu)
23540 23560 23580 23600 23620 23640 23660 23680 23700 23720 23740 23760 23780 23800 23820 23840 23860 23880 23900 23920 23940 23960 23980
Mcalc: 23746.63
Mexp: 23746.50
Error: 5.5ppm
![Page 11: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/11.jpg)
DTT Reduced mAb: Deconvoluted Spectrum of Heavy
Chain
Δ1446.6
Δ162.7
4 x10
0
1
2
3
4
5 50675.58
49228.96
50838.33
49435.14 51023.43 50121.16 49920.85 49009.52
Counts vs. Deconvoluted Mass (amu)
48600 48800 49000 49200 49400 49600 49800 50000 50200 50400 50600 50800 51000 51200
Mcalc: 50675.47
Mexp: 50675.58
Error: 2.2ppm
![Page 12: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/12.jpg)
Deconvoluted Mass Spectrum of Fc Fragment
Δ1445.8
Δ2890.93
Δ162.47
5 x10
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2 52755.64
49864.71
51309.87
47485.72
50272.22
Counts vs. Deconvoluted Mass (amu)
44000 44500 45000 45500 46000 46500 47000 47500 48000 48500 49000 49500 50000 50500 51000 51500 52000 52500 53000 53500 54000 54500 55000
5 x10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2 52755.64
52918.11
52553.59 53081.26
Counts vs. Deconvoluted Mass (amu)
52200 52400 52600 52800 53000 53200 53400 53600
Mcalc: 52755.62
Mexp: 52755.64
Error: 0.4ppm
![Page 13: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/13.jpg)
Deconvoluted Mass Spectrum of FAB fragment
Fab fragment
Mcalc: 48046.18
Mexp: 48046.09
Error: 1.8ppm
![Page 14: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/14.jpg)
Summary – Intact mAb Characterization Results
from HPLC-Chip Accurate Mass QTOF Analyses
Mcalc Mexp Error (ppm)
Intact
major glycoform 148,811.95 148,812.81 5.8
deglycosylated 145,923.24 145,924.41 8
Light chain 23,746.63 23,746.50 5.5
Heavy chain
major glycoform 50,675.47 50,675.58 2.2
Fc
major glycoform 52,755.62 52,755.64 0.4
FAB 48,046.18 48,046.09 1.8
![Page 15: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/15.jpg)
To the Instrument . . .
Let’s inject an intact protein and
perform manual and automated
data analysis
![Page 16: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/16.jpg)
Peptide Mapping of mAb: 1290 Infinity HPLC with
Accurate Mass QTOF
![Page 17: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/17.jpg)
HPLC Parameters for Poroshell-120 SB-C18 2.7µm 3x150 mm
Time %B
0 2
3 2
13 45
15 65
15.1 90
17 90
18 2
Flow – 0.3 mL/min
Stop time – 20min
Initial Solvent – 2% B
Column Temp – 40C
A: Water, 0.1% Formic Acid
B: ACN, 0.1% Formic Acid
![Page 18: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/18.jpg)
5 Replicate Runs of mAb Tryptic Peptide Map on
Poroshell 120 Column
![Page 19: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/19.jpg)
BioConfirm Molecular Feature Extractor of
Stratagene mAb Trypsin Peptide Map
![Page 20: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/20.jpg)
BioConfirm Sequence Coverage of Stratagene
mAb
![Page 21: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/21.jpg)
Glycan Characterization: Agilent 7100 Capillary Electrophoresis-LIF with
Accurate Mass TOF
![Page 22: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/22.jpg)
Page 22
• Widest choice of detctors
DAD, LIF, CCD, Single-Q, IT, TOF, QQQ, QTOF, ICP-MS
• Only vendor for plug & spray ESI-MS
complete CE-MS portfolio with a single interface solution
• Easy change from LC-MS to CE-MS and back
quick and robust ESI by MS-adaptor & spray needle kit
using Agilent Chemstation software
• Combined detection option
UV-DAD plus MS detection, LIF plus MS detection
• Grounded CE capillary end No compromises between separation- or ESI-spray voltage
Agilent 7100 Capillary Electrophoresis The CE-MS advantage
CE-Electrospray is a powerful method for high resolution separation and identification for a
wide variety of molecules. Additionally it is an orthogonal separation technique to HPLC
The Agilent interface combines the advantage of a grounded CE capillary end with a robust
and easy to use spray needle that fits into the whole portfolio of Agilent MS instruments
![Page 23: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/23.jpg)
Sheath Liquid Addition and Sprayer
Physical Setup
CE
MS
Pump
•Sheath liquid can be added by:
•infusion pump, or
•LC pump + splitter
sprayer tip
CE capillary
sheath liquid line
nebulizing gas line
screw for precise adjustment of the CE capillary
![Page 24: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/24.jpg)
• Important post-translational modification of proteins
• Pharmaceutical relevance – New Chemical Entities New Biological Entities
• Glycosylation pattern strongly influences therapeutic efficacy of antibodies
• Analysis of N-Glycan Important for Research and QA of therapeutic antibodies
N-Glycan Analysis of Monoclonal Antibodies
![Page 25: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/25.jpg)
Negatively Charged Sialylated Glycans
A1F
MW 2077.7455
A2
MW
2222.783
A2F
MW 2367.8336
![Page 26: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/26.jpg)
Extracted Ion Electropherogram of A1F, A2, and A2F
Glycans
A1F
A2F
A2
![Page 27: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/27.jpg)
Mass Spectra of A1F, A2, and A2F Glycans
A2F
A2
A1F
![Page 28: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/28.jpg)
Glycan Characterization: mAb-Glyco HPLC-Chip with
Accurate Mass TOF
![Page 29: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/29.jpg)
Glycoprotein
PNGase F
Glycosylamine
N-Glycan
-NH3
• MALDI-TOF/MS
• LC/MS
• HPLC w/ pulsed amperiometric detection
Anomeric equilibrium
2-AB
labelling agent
Reductant
labelled N-Glycan
• HPLC w/ fluorescence detection
• CE w/ fluorescence detection
Enzymatic N-Glycan cleavage using PNGase F
![Page 30: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/30.jpg)
PNGase F, Enzymatic
N-glycan Release
N-Glycan Concentration
HPLC Analysis
4 minutes
6 seconds
12 minutes
TOF MS Detector
mAb sample
Experim
enta
l Tim
e
LC- or CE- Fluorescence
10-30min
3-8 hours
2-4 days
mAb-Glyco-
Chip-MS
MALDI MS
//
//
On-Chip Glycan Characterization
Time:<30 minutes
![Page 31: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/31.jpg)
Chip Features Inner-outer Rotor Design allows for the reactor isolation from the cap-pump flow path
(a) enzyme reactor
(b) enrichment
(c) separation column
![Page 32: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/32.jpg)
Cap-pump flow rate: 3 ul/min
Empty ER volume: 310 nl
On-chip deglycosylation time: Variable – e.g. 4 min
The experimental workflow of the mAb-Glyco
Chip comprised 5 fully automated steps:
Inner and Outer Rotor Design
![Page 33: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/33.jpg)
Glycan Profile in 12 minutes
Total analysis time of 12 min with
reasonable chromatographic
resolution
A ... Sample loading
B ... ER fill
C ... Deglycolsyation
D ... Glycan Transfer
E ... Glycan Analysis
„Sample Prep“ = 6min
„Sample Analysis“ = 6min
![Page 34: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/34.jpg)
Glycan Quantitation and Report Generation
Glycan database is an accurate mass and structure database with 144 entires of glycans
that are frequently found on mAb‘s.
Reporting templates automatically processes the glycan hits by clustering and merging
isomermic structures and thus significantly helps to deliver fast answers
Glycan
Database
Reporting
Templates
![Page 35: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/35.jpg)
Comparison of mAb-Glyco Chip with CE and MALDI
MS
0
10
20
30
40
50
60
70
Man-5 G0-GlcNAc G0-F G0 G1 G2
Re
lati
ve
mo
lar
dis
trib
uti
on
[m
ol%
]
MALDI-MS (N=34)
CE-LIF (N=43)
Agilent Glycan Workflow Chip (N=50)
Agilent Glycan Workflow Chip (N=50)
Agilent Glycan Workflow Chip (N=50)
![Page 36: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/36.jpg)
mAb-Glyco Chip Reproducibility
![Page 37: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/37.jpg)
Chip Enables Fast Separation of Isomers:
Detection of Immunogenic glycan isomers from mAb made in Mouse NSO Cell
G2 structure
Potential
immunogenic
G2 structure
1786.650 amu
![Page 38: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/38.jpg)
Figure
EIC
EIC
EIC
% G0 = 46 %
% G1 = 41 %
% G2 = 13 %
EIC
EIC
EIC
% G0 = 74 %
% G1 = 24 %
% G2 = 2 %
EIC
EIC
EIC
% G0 = 49 %
% G1 = 36 %
% G2 = 5 %
Biosimilar m-2 Biosimilar m-3 Biosimilar m-1
• Dissimilar glycan distribution within biosimilars m1 – m3
• Biosimilar-m1: Similar glycan distribution as compared to innovator
N-glycan Analysis of Three Biosimilars Using mAb-
Glyco-Chip and Q-TOF
![Page 39: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/39.jpg)
Similarities and Differences – Analyzing the data by principle component analysis (Agilent Mass Profiler Pro)
Biosimilar m-1
Biosimilar m-3
1
2
3
Biosimilar m-2
• Samples from the same
manufacturer clearly cluster together.
• Three clusters obtained for three
biosimilars.
Poster: ASMS 2010: Shiaw-Lin Wu1, Yi Wang1, Ning Tang2, Dayin Lin2, William S. Hancock1, and Barry Karger1 1 Barnett Institute and Department of Chemistry and Chemical Biology, Boston, MA 02115. 2 Agilent Technologies, Waldbronn, Germany 76337
![Page 40: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/40.jpg)
Thank You
![Page 41: Characterization of Biologics Using Agilent TOF for the reactor isolation from the cap-pump flow path (a) enzyme reactor (b) enrichment (c) separation column Cap-pump flow rate: 3](https://reader031.fdocuments.in/reader031/viewer/2022030602/5ad01fd57f8b9aca598d4aa3/html5/thumbnails/41.jpg)
References
PUB # Title
5990-
3445EN
Primary Characterization of a Monoclonal Antibody
Using Agilent HPLC-Chip Accurate-Mass LC/MS
Technology
5990-
4587EN
Peptide Mapping of a Monoclonal Antibody using a
Microfluidic-based HPLC-Chip coupled to an
Agilent Accurate-Mass Q-TOF LC/MS
5990-
5190EN
Glycopeptide and Glycan Analysis of Monoclonal
Antibodies using a Microfluidic-based HPLC-Chip
coupled to an Agilent Accurate-Mass Q-TOF
LC/MS
5989-
5893EN
Antibody Analysis by ESI-TOF LC/MS
5989-
7406EN
Accurate Mass LC/TOF MS for Molecular Weight
Confirmation of Intact Proteins